SEC Filings

Form Description Filing date View
10-K/A

Amendment to a previously filed 10-K

View HTML
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
10-K

Annual report which provides a comprehensive overview of the company for the past year

View HTML
SC 13G

A statement of beneficial ownership of common stock by certain persons

View HTML
SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline